Aaron Berger, MD, Author at Grand Rounds in Urology

Aaron Berger, MD

Aaron Berger, MD, is the current Chief Medical Officer, Director of Clinical Research, and Vice President of Associated Urological Specialists in Chicago, Illinois. Dr. Berger has a special interest in prostate cancer from robotic surgery to state of the art treatments of advanced and metastatic prostate cancer. He also has extensive experience in BPH procedures such as Urolift, Rezum, and Greenlights laser therapy. He is fellowship trained in complex kidney stones and also has an interest in ED and penile implant surgery.

Dr. Berger earned his Bachelor of Science degree from the University of Wisconsin with a major in biochemistry and molecular biology. Dr. Berger attended medical school at the David Geffen School of Medicine at University of California Los Angeles to earn his M.D. He completed his residency in Urology at the NYU Langone Medical Center in New York. Dr. Berger completed a fellowship at the University of California San Francisco in Laparoscopy, Endourology and Robotic Surgery.

Dr. Berger is a member of the American Urological Association, the Endourological Society, the American Medical Association and the Chicago Urologic Society.

Talks by Aaron Berger, MD

Urologist Led Advanced Prostate Cancer Practice Tips, Tricks and Pitfalls

Posted by Aaron Berger, MD | Dec 2024

Aaron Berger, MD, delivers an in-depth discussion on the evolution and importance of urology-led advanced prostate cancer practices. In this 21-minute presentation, Dr. Berger traces the transformation of urological management from limited ADT to a multidisciplinary and pathway-driven approach today. Berger highlights the pivotal moments, such as the introduction of immunotherapy, effective oral options, and advancements in imaging guidelines, which allowed urologists to retain and expand their roles in treating advanced prostate cancer. He emphasizes the establishment of specialized clinics as critical, enabling comprehensive care through navigation systems, in-office dispensaries, and dedicated teams. Collaboration with radiation and medical oncologists is vital for managing complex cases and adopting innovations like PSMA-based therapies and triple therapy.

Optimal Management of Biochemically Recurrent Nonmetastatic Prostate Cancer

Posted by Aaron Berger, MD | Dec 2024

Aaron Berger, MD, delves into the evolving landscape of non-metastatic castration-sensitive prostate cancer (nmCSPC) and high-risk biochemical recurrence, focusing on diagnostic and therapeutic updates. In this 7-minute presentation, Dr. Berger emphasizes advanced imaging, particularly PSMA PET scans, as the diagnostic standard due to its superior sensitivity over conventional CT and bone scans.

Dr. Berger discusses treatment strategies, including salvage radiation therapy and the use of androgen deprivation therapy (ADT). For radiation-treated patients, focal salvage therapies, including cryoablation, HIFU, and electroporation, are discussed as options. The presentation underscores the shrinking non-metastatic space due to advancements in imaging technology that now frequently identify micrometastases.

Dr. Berger reinforces the importance of genetic testing and surveillance protocols involving regular PSA monitoring and imaging triggered by symptoms or PSA progression. He highlights the dynamic shifts in prostate cancer management, driven by improved diagnostics and the integration of advanced systemic therapies within an increasingly precise treatment paradigm.